Fig. 1
From: FGF18 alleviates sepsis-induced acute lung injury by inhibiting the NF-κB pathway
FGF18 expression is increased in ALI mice and LPS-treated HUVECs. (A) Schematic diagram demonstrates the animal experiment design. (B) Hematoxylin–eosin staining in lung tissues of C57BL/6J mice after PBS or LPS injection for 6 h, 12 h, and 24 h. (n = 5 per group, Scale bar = 50 μm). (C) Western blotting was performed and quantitatively analyzed to determine the protein levels of FGF18 in the lungs from LPS and PBS-treated controls. (n = 4 per group). (D) qRT-PCR analysis of the mRNA levels of FGF18 in the lungs of ALI or sham. (n = 3 per group). (E) Representative immunofluorescent staining analysis of FGF18 proteins in the lung tissues from ALI and sham. (n = 5 per group, Scale bar = 150 μm) (F) FGF18-CreERT2-ROSA26-td Tomato mice were intraperitoneally injected with 75 mg/kg of tamoxifen dissolved in corn oil for 2 weeks, followed by LPS tracheal infusion. (G) Immunofluorescent staining of CD34 (green), td Tomato (red), and DAPI (blue) in FGF18-CreERT2-ROSA26-td Tomato mice were detected. (Scale bar = 50 μm). (H) Immunofluorescent staining of CD34 (green), FGF18 (red), and DAPI (blue) in C57BL/6J mice were detected. (Scale bar = 50 μm). (I) Western blotting was performed and quantitatively analyzed to determine the protein levels of FGF18 in HUVECs. (n = 4 per group). (J) qRT-PCR analysis of the mRNA levels of FGF18 in HUVECs. (n = 4 per group). (K) Immunofluorescent staining of FGF18 (red) and DAPI (blue) in HUVECs were detected. (Scale bar = 50 μm)